Dr. Gregory Schultz reports

KANE BIOTECH FILES NEW PATENT ON REVYVE(TM) ANTIMICROBIAL WOUND GEL SPRAY

Kane Biotech Inc. has filed a patent on its revyve anti-microbial wound gel spray, a follow-on product to its Food and Drug Administration 510(k) cleared revyve anti-microbial wound gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.

"Kane has taken their revyve anti-microbial wound gel and loaded it into this new, patent-pending delivery system creating a highly differentiated product ideal for burns and other sensitive wounds," stated Dr. Gregory Schultz, chief scientific officer of Kane Biotech.

"The spray application makes it very easy to apply to the wound, and its thermo-reversible properties allow the gel to adhere to the skin on contact and makes it very easy to rinse off with cool water. This eliminates any need for direct physical contact with the burn wound and reduces the risk of infection as well as pain for the patient. I expect the product to be well received at this conference."

Kane is in the final stages of development of this product which is still pending FDA clearance. "We believe this new application system, with its optimum spray pattern, will have such a significant impact on treating sensitive wounds, in particular burns, that Kane has filed a patent," said Marc Edwards, chief executive officer of Kane Biotech. "We are very excited about this product and are working towards a commercial launch by the end of 2024."

The Boswick Burn and Wound Care Symposium is an international conference that covers the latest advancements in wound healing, burn care and infection control.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets, and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions.

We seek Safe Harbor.